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ABSTRACT
In this time of ever-increasing incidence and mortality of cancer, genetic testing 
may be greatly valuable in determining appropriate clinical management. It is 
unfortunate that the result of these tests might be problematic. With positive 
result, patients should discuss with their clinicians what to do next. Patients with 
negative result might breathe out in relief from unnecessary intensive surveillance 
and prophylaxis, yet there is Variants of Uncertain Significance (VUS).
Nowadays, VUS has become a challenging aspect in clinical management of 
cancer. Clinicians are expected to deliver the interpretation of test results with 
certainty, while they could not put aside the confounding factors of genetic 
testings. 
BRCA1 and BRCA2 are two genes with high penetrance in breast cancer. The 
impact of their mutation would only manifest when there is loss of heterozygosity, 
as BRCA1/2 are tumor suppressor genes and DNA repair regulators. Mutation of 
BRCA1/2 gene is demonstrated within the tissue specimen and blood sample 
DNA, proving that it has occupied all tissues and thus inheritable.
In the case of BRCA1/2 mutations, 10-20% of all genetic tests will result in 
VUS. One previous study of sixteen Indonesian patients, 13 (81,25%) patients 
had VUS. There were variants that had not been found in other population. The 
reclassification of VUS in BRCA1/2 gene is not only a challenge to clarify its 
clinical impacts, but also an obligation to our community for further contribution 
in science.
There can be a set of factors suggesting that VUS might be a deleterious mutation:
 1. Co-segregation: when the variant comes with multiple and multigenerational 
incidence of cancer, VUS is possible.
 2. Epidemiology: when a case-control study demonstrates discrepancy in 
prevalence, VUS is possible.
 3. Co-occurrence with deleterious mutation: when the variant is shared within 
the same gene in other individuals, VUS is possible.
 4. Evolutionary data: when the sequence is carried across species, VUS is 
possible.
 5. Amino acid substitution: when the substitute is structurally similar, VUS is 
impossible.
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